본문 바로가기
KERD
논문KCI 등재

Autoantibody Encephalitis: Presentation, Diagnosis, and Management

Eric Lancaster
대한신경과학회 (Korean Neurological Association)|2022.07|Journal of Clinical Neurology|제18권 제4호|pp. 373-390

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

antibodyencephalitisparaneoplasticcerebellar ataxiaanti-NMDAR encephalitis.

초록

Autoantibody encephalitis causes distinct clinical syndromes involving alterations in mentation, abnormal movements, seizures, psychiatric symptoms, sleep disruption, spasms, and neuromyotonia. The diagnoses can be confirmed by specific antibody tests, although some antibodies may be better detected in spinal fluid and others in serum. Each disorder conveys a risk of certain tumors which may inform diagnosis and be important for treatment. Autoantibodies to receptors and other neuronal membrane proteins are generally thought to be pathogenic and result in loss of function of the targets, so understanding the pharmacology of the receptors may inform our understanding of the syndromes. Patients may be profoundly ill but the syndromes usually respond to immune therapy, although there are differences in the types of immune therapy that are thought to be most effective for the various disorders.

Abstract

Autoantibody encephalitis causes distinct clinical syndromes involving alterations in mentation, abnormal movements, seizures, psychiatric symptoms, sleep disruption, spasms, and neuromyotonia. The diagnoses can be confirmed by specific antibody tests, although some antibodies may be better detected in spinal fluid and others in serum. Each disorder conveys a risk of certain tumors which may inform diagnosis and be important for treatment. Autoantibodies to receptors and other neuronal membrane proteins are generally thought to be pathogenic and result in loss of function of the targets, so understanding the pharmacology of the receptors may inform our understanding of the syndromes. Patients may be profoundly ill but the syndromes usually respond to immune therapy, although there are differences in the types of immune therapy that are thought to be most effective for the various disorders.

참고문헌 (126)

  1. Gleichman AJ, "Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain", J Neurosci, 32, pp.11082~11094 (2012)
  2. Gleichman AJ, "Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis", Ann Clin Transl Neurol, 1, pp.180~189 (2014)
  3. Olsen AL, "Caspr2 autoantibodies target multiple epitopes", Neurol Neuroimmunol Neuroinflamm, 2, pp.e127~ (2015)
  4. Rauschenberger V, "Glycine receptor autoantibodies impair receptor function and induce motor dysfunction", Ann Neurol, 88, pp.544~561 (2020)
  5. Lindstrom J, "Myasthenogenicity of the main immunogenic region", Ann N Y Acad Sci, 1274, pp.9~13 (2012)
  6. Greene M, "Delta", Notch-Like EGF-related receptor(DNER)is not a Notch ligand, 2016, pp.11, e0161157~
  7. Dalmau J, "Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis", Lancet Neurol, 10, pp.63~74 (2011)
  8. Makarovsky I, "Strychnine--a killer from the past", Isr Med Assoc J, 10, pp.142~145 (2008)
  9. Carvajal-González A, "Glycine receptor antibodies in PERM and related syndromes : characteristics, clinical features and outcomes", Brain, 137(Pt 8), pp.2178~2192 (2014)
  10. Szabo A, "HuD, a paraneoplastic encephalomyelitis antigen, contains RNAbinding domains and is homologous to Elav and Sex-lethal", Cell, 67, pp.325~333 (1991)
  11. Okano HJ, "A hierarchy of Hu RNA binding proteins in developing and adult neurons", J Neurosci, 17, pp.3024~3037 (1997)
  12. Sillevis Smitt PA, "Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice", Neurology, 45, pp.1873~1878 (1995)
  13. Bernal F, "Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis", Acta Neuropathol, 103, pp.509~515 (2002)
  14. Greenlee JE, "Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures", J Neuropathol Exp Neurol, 69, pp.997~1007 (2010)
  15. Graus F, "Anti-Hu-associated paraneoplastic encephalomyelitis : analysis of 200 patients", Brain, 124, pp.1138~1148 (2001)
  16. Moscato EH, "Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition : insights from molecular, cellular and synaptic studies", Eur J Neurosci, 32, pp.298~309 (2010)
  17. Planagumà J, "Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice", Brain, 138(Pt 1), pp.94~109 (2015)
  18. Planagumà J, "Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity", Ann Neurol, 80, pp.388~400 (2016)
  19. Peng X, "Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid(AMPA)receptor encephalitis antibodies", Ann Neurol, 77, pp.381~398 (2015)
  20. Landa J, "Encephalitis with autoantibodies against the glutamate kainate receptors GluK2", Ann Neurol, 90, pp.101~117 (2021)
  21. Ohkawa T, "Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors", J Neurosci, 33, pp.18161~18174 (2013)
  22. Davies AM, "Human IgG4 : a structural perspective", Immunol Rev, 268, pp.139~159 (2015)
  23. Gadoth A, "Elevated LGI1-IgG CSF index predicts worse neurological outcome", Ann Clin Transl Neurol, 5, pp.646~650 (2018)
  24. Huijbers MG, "The expanding field of IgG4-mediated neurological autoimmune disorders", Eur J Neurol, 22, pp.1151~1161 (2015)
  25. Hara M, "DPPX antibody-associated encephalitis : main syndrome and antibody effects", Neurology, 88, pp.1340~1348 (2017)
  26. Gresa-Arribas N, "Human neurexin-3α antibodies associate with encephalitis and alter synapse development", Neurology, 86, pp.2235~2242 (2016)
  27. Dalakas MC, "IgG4-mediated neurologic autoimmunities : understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and longlasting benefits of anti-B cell therapies", Neurol Neuroimmunol Neuroinflamm, 9, pp.e1116~ (2022)
  28. Tüzün E, "Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma", Acta Neuropathol, 118, pp.737~743 (2009)
  29. Pittock SJ, "Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study", Lancet Neurol, 12, pp.554~562 (2013)
  30. Höftberger R, "Encephalitis and GABAB receptor antibodies : novel findings in a new case series of 20 patients", Neurology, 81, pp.1500~1506 (2013)
  31. Muñiz-Castrillo S, "Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis", Neurol Neuroimmunol Neuroinflamm, 8, pp.e974~ (2021)
  32. McCracken L, "Improving the antibody-based evaluation of autoimmune encephalitis", Neurol Neuroimmunol Neuroinflamm, 4, pp.e404~ (2017)
  33. Ruiz-García R, "Limitations of a commercial assay as diagnostic test of autoimmune encephalitis", Front Immunol, 12, pp.691536~ (2021)
  34. Gresa-Arribas N, "Sensitivity of antibody testing, clinica-titer correlations, and epitope repertoire in anti-NMDAR encephalitis", Ann Neurol, 74, pp.S25~ (2013)
  35. Gresa-Arribas N, "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis : a retrospective study", Lancet Neurol, 13, pp.167~177 (2014)
  36. Graus F, "A clinical approach to diagnosis of autoimmune encephalitis", Lancet Neurol, 15, pp.391~404 (2016)
  37. Graus F, "Recommended diagnostic criteria for paraneoplastic neurological syndromes", J Neurol Neurosurg Psychiatry, 75, pp.1135~1140 (2004)
  38. Clowse ME, "Ovarian preservation by GnRH agonists during chemotherapy:a meta-analysis", J Womens Health(Larchmt), 18, pp.311~319 (2009)
  39. Nosadini M, "Mycophenolate mofetil in paediatric autoimmune or immune-mediated diseases of the central nervous system : clinical experience and recommendations", Dev Med Child Neurol, 61, pp.458~468 (2019)
  40. Titulaer MJ, "Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men", Neurology, 82, pp.550~551 (2014)
  41. Florance NR, "Anti-N-methyl-D-aspartate receptor(NMDAR)encephalitis in children and adolescents", Ann Neurol, 66, pp.11~18 (2009)
  42. Titulaer MJ, "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study", Lancet Neurol, 12, pp.157~165 (2013)
  43. Yeshokumar AK, "Gait disturbance as the presenting symptom in young children with anti-NMDA receptor encephalitis", Pediatrics, 138, pp.e20160901~ (2016)
  44. Gordon-Lipkin E, "Comparative outcomes in children and adults with anti-N-methyl-D-aspartate(anti-NMDA)receptor encephalitis", J Child Neurol, 32, pp.930~935 (2017)
  45. Titulaer M, "Clinical features, treatment, and outcome of 500 patients with anti-NMDA receptor encephalitis", Neurology, 78(1 Supplement), pp.PL01.001~ (2012)
  46. Ances BM, "Treatment-responsive limbic encephalitis identified by neuropil antibodies : MRI and PET correlates", Brain, 128(Pt 8), pp.1764~1777 (2005)
  47. Gill A, "A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes", J Neuroimmunol, 334, pp.576980~ (2019)
  48. Kobayashi Y, "An elderly case of paraneoplastic anti-NMDA receptor encephalitis associated with small-cell lung cancer expressing NR1subunits", Intern Med, 59, pp.2307~2309 (2020)
  49. Dalmau J, "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma", Ann Neurol, 61, pp.25~36 (2007)
  50. Deng S, "Clinical characteristics and short-term prognosis of autoimmune encephalitis : a single-center cohort study in Changsha, China", Front Neurol, 10, pp.539~ (2019)
  51. Armangue T, "Herpes simplex virus encephalitis is a trigger of brain autoimmunity", Ann Neurol, 75, pp.317~323 (2014)
  52. Höftberger R, "Clinical neuropathology practice guide 4-2013 : post-herpes simplex encephalitis : N-methyl-Daspartate receptor antibodies are part of the problem", Clin Neuropathol, 32, pp.251~254 (2013)
  53. Salovin A, "Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection", Neurol Neuroimmunol Neuroinflamm, 5, pp.e458~ (2018)
  54. Balu R, "A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis", Neurology, 92, pp.e244~e252 (2019)
  55. Schmitt SE, "Extreme delta brush : a unique EEG pattern in adults with anti-NMDA receptor encephalitis", Neurology, 79, pp.1094~1100 (2012)
  56. Sonderen AV, "Predictive value of electroencephalography in anti-NMDA receptor encephalitis", J Neurol Neurosurg Psychiatry, 89, pp.1101~1106 (2018)
  57. Kerik-Rotenberg N, "A metabolic brain pattern associated with anti-N-methyl-D-dspartate receptor encephalitis", Psychosomatics, 61, pp.39~48 (2020)
  58. Probasco JC, "Electroencephalographic and fluorodeoxyglucose-positron emission tomography correlates in anti-N-methyl-d-aspartate receptor autoimmune encephalitis", Epilepsy Behav Case Rep, 2, pp.174~178 (2014)
  59. Probasco JC, "Abnormal brain metabolism on FDG-PET", CT is a common early finding in autoimmune encephalitis, 2017, pp.4, e352~
  60. Martinez-Hernandez E, "Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies", Neurology, 94, pp.e2302~e2310 (2020)
  61. Titulaer MJ, "Overlapping demyelinating syndromes and anti–Nmethyl-D-aspartate receptor encephalitis", Ann Neurol, 75, pp.411~428 (2014)
  62. Lim JA, "Frequent rhabdomyolysis in anti-NMDA receptor encephalitis", J Neuroimmunol, 298, pp.178~180 (2016)
  63. de Bruijn MAAM, "Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis", Neurology, 92, pp.e2185~e2196 (2019)
  64. Wang T, "Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor(anti-NMDAR)encephalitis as well as the clinical characteristics : an observational study", J Neuroimmunol, 354, pp.577527~ (2021)
  65. Scheibe F, "Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis", Neurology, 88, pp.366~370 (2017)
  66. Lee WJ, "Teratoma removal, steroid, IVIG, rituximab and tocilizumab(T-SIRT)in anti-NMDAR encephalitis", Neurotherapeutics, 18, pp.474~487 (2021)
  67. Hu F, "Novel findings of HLA association with anti-LGI1 encephalitis : HLA-DRB1*03 : 01and HLA-DQB1*02 : 01", J Neuroimmunol, 344, pp.577243~ (2020)
  68. Lai M, "Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels : a case series", Lancet Neurol, 9, pp.776~785 (2010)
  69. Irani SR, "Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis", Ann Neurol, 69, pp.892~900 (2011)
  70. van Sonderen A, "Anti-LGI1 encephalitis : clinical syndrome and long-term follow-up", Neurology, 87, pp.1449~1456 (2016)
  71. Rodriguez A, "LGI1 antibody encephalitis : acute treatment comparisons and outcome", J Neurol Neurosurg Psychiatry, 93, pp.309~315 (2022)
  72. van Sonderen A, "Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4", Ann Neurol, 81, pp.193~198 (2017)
  73. Kim TJ, "Anti-LGI1encephalitis is associated with unique HLA subtypes", Ann Neurol, 81, pp.183~192 (2017)
  74. Peris Sempere V, "Human leukocyte antigen association study reveals DRB1*04 : 02 effects additional to DRB1*07 : 01 in anti-LGI1 encephalitis", Neurol Neuroimmunol Neuroinflamm, 9, pp.e1140~ (2022)
  75. Irani SR, "Effect of rituximab in patients with leucine-rich, glioma-inactivated 1antibody-associated encephalopathy", JAMA Neurol, 71, pp.896~900 (2014)
  76. Brown JW, "Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis", J Neuroimmunol, 271, pp.66~68 (2014)
  77. Lai M, "AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location", Ann Neurol, 65, pp.424~434 (2009)
  78. Höftberger R, "Encephalitis and AMPA receptor antibodies : novel findings in a case series of 22 patients", Neurology, 84, pp.2403~2412 (2015)
  79. Hutchinson M, "Progressive encephalomyelitis, rigidity, and myoclonus : a novel glycine receptor antibody", Neurology, 71, pp.1291~1292 (2008)
  80. Petit-Pedrol M, "Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor : a case series, characterisation of the antigen, and analysis of the effects of antibodies", Lancet Neurol, 13, pp.276~286 (2014)
  81. Horresh I, "Multiple molecular interactions determine the clustering of Caspr2 and Kv1 channels in myelinated axons", J Neurosci, 28, pp.14213~14222 (2008)
  82. Lancaster E, "Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia", Ann Neurol, 69, pp.303~311 (2011)
  83. Irani SR, "Morvan syndrome : clinical and serological observations in 29 cases", Ann Neurol, 72, pp.241~255 (2012)
  84. Fleisher J, "Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis", JAMA Neurol, 70, pp.1311~1314 (2013)
  85. Boronat A, "Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4. 2 potassium channels", Ann Neurol, 73, pp.120~128 (2013)
  86. Lancaster E, "Antibodies to the GABA(B)receptor in limbic encephalitis with seizures : case series and characterisation of the antigen", Lancet Neurol, 9, pp.67~76 (2010)
  87. van Coevorden-Hameete MH, "The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies", Brain, 142, pp.1631~1643 (2019)
  88. Carr I, "The Ophelia syndrome : memory loss in Hodgkin’s disease", Lancet, 1, pp.844~845 (1982)
  89. Lancaster E, "Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome", Neurology, 77, pp.1698~1701 (2011)
  90. Landa J, "Seizure-related 6 homolog like 2 autoimmunity : neurologic syndrome and antibody effects", Neurol Neuroimmunol Neuroinflamm, 8, pp.e916~ (2021)
  91. Dalmau J, "Anti-Hu--associated paraneoplastic encephalomyelitis", sensory neuronopathy. A clinical study of 71 patients, 1992, pp.71, 59~72
  92. Dalmau J, "Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis", Ann Neurol, 27, pp.544~552 (1990)
  93. Luque FA, "Anti-Ri : an antibody associated with paraneoplastic opsoclonus and breast cancer", Ann Neurol, 29, pp.241~251 (1991)
  94. Dalmau J, "Clinical analysis of anti-Ma2-associated encephalitis", Brain, 127(Pt 8), pp.1831~1844 (2004)
  95. Hoffmann LA, "Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes : 22 newly diagnosed patients and review of previous cases", J Neurol Neurosurg Psychiatry, 79, pp.767~773 (2008)
  96. Jarius S, "‘Medusa head ataxia’ : the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2 : anti-PKC-gamma, anti-GluR-delta2, anti-Ca", ARHGAP26and anti-VGCC, 2015, pp.12, 167~
  97. Jarius S, "‘Medusa-head ataxia’ : the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1 : anti-mGluR1, anti-Homer-3, anti-Sj", ITPR1 and anti-CARP VIII, 2015, pp.12, 166~
  98. Jarius S, "‘Medusa head ataxia’ : the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3 : anti-Yo", CDR2, anti-Nb, DNER, other antibodies, diagnostic pitfalls, summary and outlook, pp.J Neuroinflammation, 2015[DOI]
  99. Peterson K, "Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients", Neurology, 42, pp.1931~1937 (1992)
  100. Tian N, "The role of the synthetic enzyme GAD65 in the control of neuronal gamma-aminobutyric acid release", Proc Natl Acad Sci U S A, 96, pp.12911~12916 (1999)
  101. McKeon A, "Stiff-man syndrome and variants : clinical course, treatments, and outcomes", Arch Neurol, 69, pp.230~238 (2012)
  102. Pittock SJ, "Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction", Mayo Clin Proc, 81, pp.1207~1214 (2006)
  103. Guasp M, "Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67(GAD67)", J Neuroimmunol, 300, pp.15~17 (2016)
  104. Hadjivassiliou M, "Clinical characteristics and management of 50 patients with anti-GAD ataxia : gluten-free diet has a major impact", Cerebellum, 20, pp.179~185 (2021)
  105. de GraaffE, "Identification of delta", notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration, 2012, pp.71, 815~824
  106. Greene M, "Antibodies to Delta", notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma, 2014, pp.71, 1003~1008
  107. Coesmans M, "Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies", Ann Neurol, 53, pp.325~336 (2003)
  108. Dubey D, "Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11encephalitis", JAMA Neurol, 77, pp.1420~1429 (2020)
  109. Mandel-Brehm C, "Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis", N Engl J Med, 381, pp.47~54 (2019)
  110. Rodrigo L, "Gluten ataxia is better classified as non-celiac gluten sensitivity than as celiac disease : a comparative clinical study", Immunol Res, 64, pp.558~564 (2016)
  111. Hadjivassiliou M, "Diagnostic criteria for primary autoimmune cerebellar ataxia—guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias", Cerebellum, 19, pp.605~610 (2020)
  112. Gaspard N, "New-onset refractory status epilepticus : etiology, clinical features, and outcome", Neurology, 85, pp.1604~1613 (2015)
  113. Iizuka T, "Cryptogenic NORSE : its distinctive clinical features and response to immunotherapy", Neurol Neuroimmunol Neuroinflamm, 4, pp.e396~ (2017)
  114. Tizazu E, "Low rate of glutamic acid decarboxylase 65(GAD-65)antibodies in chronic epilepsy", Seizure, 80, pp.38~41 (2020)
  115. Peltola J, "Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy", Neurology, 55, pp.46~50 (2000)
  116. Husari KS, "Autoimmune epilepsy", Neurotherapeutics, 16, pp.685~702 (2019)
  117. Yanagida A, "Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus", Neurol Neuroimmunol Neuroinflamm, 7, pp.e849~ (2020)
  118. antibodies in patients with schizophrenia and related psychoses : a systematic review and meta-analysis, "Psychol Med", 2014, 2475~2487
  119. Titulaer MJ, "Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia : a theory with unproven links", Mol Psychiatry, 19, pp.1054~ (2014)
  120. Lancaster E, "Immunoglobulin G antibodies to the N-methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses", Ann Neurol, 77, pp.183~ (2015)
  121. Cullen AE, "Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders : a meta-analysis of cross-sectional and case-control studies", Lancet Psychiatry, 8, pp.109~120 (2021)
  122. Pollak TA, "Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis", Biol Psychiatry, 90, pp.9~15 (2021)
  123. Hoffmann C, "Absence of autoantibodies against neuronal surface antigens in sera of patients with psychotic disorders", JAMA Psychiatry, 77, pp.322~325 (2020)
  124. Graus F, "Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors", Nat Rev Clin Oncol, 16, pp.535~548 (2019)
  125. Vogrig A, "Central nervous system complications associated with immune checkpoint inhibitors", J Neurol Neurosurg Psychiatry, 91, pp.772~778 (2020)
  126. Ebright MJ, "Unintended consequences of Mayo paraneoplastic evaluations", Neurology, 91, pp.e2057~e2066 (2018)

관련 논문AI추천

Te Diagnosis and Treatment of Autoimmune EncephalitisEric Lancaster대한신경과학회 · Journal of Clinical Neurology2016 · 제12권 제1호Clinical Approach to Autoimmune Epilepsy강경욱, 김근태, 김대영, 김동욱, 노영주, 변정익, 서종근, 양광익, 이순태, 장윤혁, 조용원대한신경과학회 · Journal of Clinical Neurology2020 · 제16권 제4호Outcome and Sequelae of Autoimmune EncephalitisAlexandra Mailles, Ariane Soldatos, Felicia C. Chow, James Sejvar, Jean-Paul Stahl, Kathryn A. Kvam, Pierre Tattevin대한신경과학회 · Journal of Clinical Neurology2024 · 제20권 제1호Clinical Features and Treatment Outcomes of Seronegative Pediatric Autoimmune Encephalitis강훈철, 김세희, 김흥동, 이상보, 이준수대한신경과학회 · Journal of Clinical Neurology2021 · 제17권 제2호Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Korea: Clinical Features, Treatment, and Outcome주건, 김소연, 김영수, 김태준, 문장섭, 박경일, 변정익, 신용원, 신정원, 이건주, 이상건, 이순태, 임정아, 정근화대한신경과학회 · Journal of Clinical Neurology2014 · 제10권 제2호Confusion, Faciobrachial Dystonic Seizures, and Critical Hyponatremia in a Patient with Voltage-Gated Potassium Channel EncephalitisJulian Yaxley대한가정의학회 · Korean Journal of Family Medicine2017 · 제38권 제2호

이 간행물의 다른 논문 (17건)

Potential of Transcranial Direct Current Stimulation in Alzheimer’s Disease: Optimizing Trials Toward Clinical UseMarom Bikson, Min-Jeong Kim, Giuseppina Pilloni, Leigh E. Charvet, Nikhil Palekarpp. 391-400Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update김민경, 문소영, 박선아, 장유정, 이선민pp. 401-409Advances in Intraoperative Neurophysiology During Microvascular Decompression Surgery for Hemifacial Spasm박경석, Vedran Deletis, 김준순, 주병억pp. 410-420High-on-Aspirin Platelet Reactivity Differs Between Recurrent Ischemic Stroke Associated With Extracranial and Intracranial Atherosclerosis허성혁, 김범준, 장준영, 최혜연, 장대일, 노경철, 우호걸pp. 421-427A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer’s Disease김희진, 박미영, 한현정, Yuan-Han Yang, 한설희, Esther Gunaseli A/P M. Ebeneze, Gurudev M. Kewalram, 박기형, 박경원, 양동원, 최성혜pp. 428-436
원문 보기